|
The
slides to be stained for
S-100 comprised:
1: malignant melanoma
(small intestine), 2: brain, 3: malignant melanoma (testis),
4: appendix, 5: blue nevus.
Criteria for assessing a staining as optimal
included: strong
and distinct nuclear and cytoplasmatic staining reaction in the
tumor cells of the malignant melanomas and the blue naevus. Glial cells, Schwann cells, fat cells, and reticulum cells including
epidermal Langerhans cells should also be demonstrated.
63 laboratories submitted stainings. At the assessment,
19 obtained an optimal
result (30%), 26 good (41%), 10 borderline (16%) and 8 poor
(13%)
55 used pAb Z0311 (DakoCytomation), 3 pAb
760-2523 (Ventana), 1
pAb NCL-S100p (Novocastra), 1 pAb (BioMeda), 1 mAb DAK-S100B/2 (DakoCytomation), 1 mAb 15E2E2 (BioGenex), and 1 mAb S1/61/69 (Novocastra).
|
 |
|
Mandatory for an optimal result in
this assessment was the use of pAb Z0311. Pre-treatment was used
for all but one of the optimal stainings.
The protocol without pretreatment
used
prolonged incubation time and a high Ab concentration.
HIER and proteolytic
pre-treatment seemed equally useful. However, slight differences in
the staining patterns were
seen with these two pre-treatment methods:
Using HIER, the dendritic cell in the germinal centres were
stained, while they were unstained after proteolytic pretreament.
Most protocols gave a good
staining of the malignant melanomas, while only the optimal
protocols gave a proper staining of the blue naevus.
The most frequent causes of
insufficient stainings (often in combination) were:
- Inappropriate Ab
- A too low primary
Ab
concentration
- A too high primary
Ab concentration
after epitope retrieval
-
Lack of pre-treatment
- Excessive proteolytic pre-treatment.
|